|
Unit:
|
Putian Meizhou Bay North Bank Economic Development Zone Management Committee
|
|
|
Project Area:
|
putian
|
|
|
Industry:
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode:
|
Individual Proprietorship,Joint Venture,Collaborate,Land User
|
|
|
Nature of Project:
|
Encourage
|
|
|
Working Progress in Prior Period:
|
In the process of attracting investment
|
|
|
Total Investment:
|
1 million yuan
|
|
|
Expected to Attract Investment:
|
0.8 million yuan
|
|
|
Reason and Condition:
|
The total planned area of the Biotech Park on both sides of the north bank is 7500 acres, with an actual available land of approximately 6000 acres. The first phase has completed 10 factories (including standard factories and customized factories), with a total construction area of approximately 100000 square meters. The supporting comprehensive service center includes 3 talent apartments, 1 technology incubation center, 2 scientific research centers, and 1 exchange center and affiliated building, with a total area of approximately 92000 square meters. At the same time, the park is adjacent to Mazu Health City, and related infrastructure is shared.
|
|
|
Content and Scale:
|
Using the Cross Strait Biotechnology Park as a carrier, we will focus on introducing production and sales projects for traditional Chinese medicine, natural drugs, raw materials, and formulations; Medical device production, operation, and sales industry projects; Develop projects such as the processing, production, and trade of health products and specialty medical foods, cosmetics, beauty equipment, traditional Chinese medicine decoction pieces, and pharmaceutical equipment exhibition and sales centers.
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.